Palisade Bio, Inc. (NASDAQ:PALI) Sees Large Increase in Short Interest

Palisade Bio, Inc. (NASDAQ:PALI) was the recipient of a large increase in short interest in December. As of December 15th, there was short interest totalling 1,840,000 shares, an increase of 1,610.0% from the November 30th total of 107,600 shares. Based on an average trading volume of 1,220,000 shares, the short-interest ratio is presently 1.5 days. Currently, 67.7% of the company’s stock are short sold.

Analyst Upgrades and Downgrades

PALI has been the topic of a number of recent analyst reports. Brookline Capital Management assumed coverage on shares of Palisade Bio in a report on Wednesday, November 20th. They issued a “buy” rating and a $38.00 price target on the stock. Maxim Group lowered their price objective on Palisade Bio from $22.50 to $8.00 and set a “buy” rating for the company in a research report on Wednesday, November 13th.

Palisade Bio Stock Down 5.6 %

Shares of Palisade Bio stock traded down $0.10 during midday trading on Friday, hitting $1.67. The company had a trading volume of 145,130 shares, compared to its average volume of 661,725. The stock has a market cap of $2.53 million, a price-to-earnings ratio of -0.12 and a beta of 1.39. Palisade Bio has a 12-month low of $1.38 and a 12-month high of $22.35. The company has a fifty day simple moving average of $2.45 and a 200 day simple moving average of $3.41.

Palisade Bio (NASDAQ:PALI) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($2.32) EPS for the quarter, topping the consensus estimate of ($3.35) by $1.03. As a group, analysts expect that Palisade Bio will post -12.43 EPS for the current year.

Institutional Trading of Palisade Bio

A hedge fund recently bought a new stake in Palisade Bio stock. JPMorgan Chase & Co. bought a new stake in Palisade Bio, Inc. (NASDAQ:PALI) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 8,200 shares of the company’s stock, valued at approximately $29,000. JPMorgan Chase & Co. owned about 0.54% of Palisade Bio as of its most recent SEC filing. Institutional investors own 11.79% of the company’s stock.

Palisade Bio Company Profile

Palisade Bio, Inc, a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage.